| Literature DB >> 35932000 |
Yasuhiro Kihara1, Hiroshi Yokomizo2.
Abstract
BACKGROUND: Postoperative cholangitis is a late complication of pancreaticoduodenectomy (PD). This study aimed to elucidate the pathogenesis of post-PD cholangitis (PPDC) and explore its optimal treatment.Entities:
Keywords: Pancreaticoduodenectomy; Postoperative cholangitis; Tokyo Guidelines 2018
Mesh:
Year: 2022 PMID: 35932000 PMCID: PMC9356454 DOI: 10.1186/s12893-022-01752-3
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1Patient enrollment flowchart
Diagnosis criteria and severity classification of PPDC based on TG18
| A. Systemic inflammation | ||
| A-1. Fever and/or shaking chills | ||
| A-2. Laboratory data: evidence of inflammatory response | ||
| B. Cholestasis | ||
| B-1. Jaundice | ||
| B-2. Laboratory data: abnormal liver function tests | ||
| C. Imaging | ||
| C-1. Biliary dilatation | ||
| C-2. Evidence of the etiology on imaging (stricture, stone, stent etc | ||
| A-1 | Fever | BT > 38 °C |
| A-2 | Evidence of inflammatory response | WBC counts: < 4000 or > 10,000 /μL CRP: > 1.0 mg/dL |
| B-1 | Jaudice | T-bil: > 2.0 mg/dL |
| B-2 | Abnormal liver function | ALP, γ-GTP, AST, ALT: > 1.5 times the institutional standard values |
PPDC post pancreaticoduodenectomy cholangitis, TG18 Tokyo Guideline 2018, BT body temperature, WBC white blood cells, CRP C-reactive protein, T-bil Total bilirubin, ALP alkaline phosphate, γ-GTP gamma-glutamyl transpeptidase, AST aspartate aminotransaminase, ALT alanine aminotransaminase
Clinical characteristics of patients (n = 176)
| Characteristic | Patients ( | Percent |
|---|---|---|
| Age, years | ||
| Median (range) | 70 (34–86) | |
| Interquartile range | 63–76 | |
| Sex | ||
| Male | 110 | 63 |
| Female | 66 | 37 |
| Body mass index (kg/m2) | ||
| Mean (SD) | 22.9 (3.2) | |
| Range | 15.4–35.3 | |
| ASA-PS | 27 | 15 |
| I | ||
| II | 138 | 78 |
| III | 10 | 5.6 |
| IV | 1 | 0.5 |
| Diabetes mellitus | 28 | 16 |
| Diagnosis | ||
| Pancreatic carcinoma | 79 | 45 |
| Cholangiocarcinoma | 47 | 27 |
| Carcinoma of the ampulla of Vater | 22 | 12 |
| Others | 28 | 16 |
| Jaundice | 82 | 47 |
| Preoperative biliary drainage | 104 | 59 |
| Preoperative cholangitis | 35 | 20 |
| Postoperative cholangitis | 19 | 11 |
| Operative time (min) | ||
| Median (range) | 451 (278–738) | |
| Interquartile range | 381–497 | |
| Blood loss (ml) | ||
| Median (range) | 594 (10–2450) | |
| Interquartile range | 330–1195 | |
| Blood transfusion | 33 | 19 |
| Width of remnant bile duct (mm) | ||
| Median (range) | 10 (4–40) | |
| Interquartile range | 8–12 | |
| Biliary stenting | 94 | 53 |
| POPF | ||
| Grade B or C | 84 | 48 |
| Bile leakage | 4 | 2.2 |
| DGE | 9 | 5.1 |
| Postoperative pneumobilia | 132 | 76 |
| Observation period (month) | ||
| Median (range) | 35 (11–115) | |
| Interquartile range | 18–58 |
SD standard deviation; POPF postoperative pancreatic fistula; DGE delayed gastric empty; ASA-PS American Society of Anesthesiologists Physical Status
Details of PPDC
| Number of affected patients | 19/176 (11%) |
|---|---|
| Total events of PPDC | 36 |
| Number of episodes of PPDC | Patients (n = 19) |
| 1 | 10 |
| 2 | 3 |
| 3 | 5 |
| 5 | 1 |
| Time from surgery to first onset (month) | Patients (n = 19) |
| ≤ 24 | 14 |
| > 24 | 5 |
| Severity according to TG18 | Total events (n = 36) |
| Mild | 21 (58%) |
| Moderate | 15 (42%) |
| Severe | 0 |
PPDC post pancreaticoduodenectomy cholanitis, TG18 Tokyo Guideline 2018
Fig. 2Changes in the blood test values of (a) WBC, (b) ALP, and (c) γ-GTP at the onset of post-PD cholangitis and after starting the initial treatment. Blood test results showed changes in the (a) white blood cell (WBC) counts, (b) alkaline phosphatase (ALP) levels, and (c) gamma-glutamyl transpeptidase (γ-GTP) values at the onset of post-pancreaticoduodenectomy cholangitis (PPDC) and after starting the initial treatment. For WBC counts, the median at the onset of PPDC and first blood test after starting treatment were 10,385 (range: 4120‒21,690) and 6000 (range: 2570‒17,260), respectively (a). The Wilcoxon signed-rank sum test for the two corresponding groups showed a statistically significant difference with P = 1.2 × 10–6 (a). For ALP level, the median at the onset of PPDC and first blood test after starting treatment were 614 (range: 204‒2890) and 516 (range: 135‒2706), respectively (b). A statistically significant difference was noted among the two corresponding groups, with P = 3.2 × 10–3 (b). For γ-GTP values, the median at the onset of PPDC and first blood test after starting treatment were 160 (range: 9‒1693) and 184 (range: 9‒1042), respectively (c). A statistically significant difference was noted among the two corresponding groups, with P = 0.016 (c)
PPDC patients blood culture results
| Total number of inspections | 24 | |
| Number of tests positive (%) | ||
| Severity of PPDC | ||
| Mild | 10 /12 (83) | |
| Moderate | 6 /12 (50) | |
| Detected bacterial species and the number of detections by severity | ||
| Number of detections by severity of PPDC | ||
| Bacteria | ||
| 7 | 4 | |
| 2 | 2 | |
| 2 | 0 | |
| 1 | 0 | |
| Others | 4 | 2 |
PPDC post pancreaticoduodenectomy cholangitis
Details of the treatment of PPDC patients
| Duration of medication (day) | ||
| All patients | 7 (3–31)a | |
| Severity of PPDC | ||
| Mild | 7 (3–26)a | |
| Moderate | 7 (5–31)a | |
| Medication for PPDC | Number of events | |
| Oral antibiotic treatment | 6 | |
| Intravenous antibiotic treatment | 27 | |
| Intravenous therapy followed by oral antibiotics | 3 | |
| First antibacterial agent administered | Number of events | |
| Sulbactam / ampicillin | 21 | |
| Ceftriaxone | 5 | |
| Levofloxacin (oral antibiotics) | 6 | |
| Others | 4 | |
| Cases with subsequent change of antibiotics | 11 | |
BD Endoscopic baloon dilation; SI Endoscopic stent insertion; EL Endoscopic lithotripsy; EO Endoscopic observation only
aData was presented as median (range)
Predictors for the development of PPDC by univariate and multivariate analysis
| Covariate | Category | PPDC | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| Positive | Negative | P value | Odds ratio (95%CI) | P value | ||
| Age (years)a | 71.7 (10.6) | 68.3 (9.90) | 0.15 | 1.04 (0.99–1.10) | 0.14 | |
| Sex | Male | 14 | 96 | 0.28 | 1.86 (0.63–5.53) | 0.26 |
| Female | 5 | 61 | ||||
| Body mass index (kg/m2)a | 22.7 (2.8) | 22.9 (3.2) | 0.86 | |||
| ASA-PS | I or II | 18 | 147 | 1.00 | ||
| III or IV | 1 | 10 | ||||
| Diabetes mellitus | Positive | 3 | 25 | 0.99 | ||
| Negative | 16 | 132 | ||||
| Diagnosis | ||||||
| Pancreatic carcinoma | 9 | 70 | 0.77 | |||
| Cholangiocarcinoma | 6 | 41 | ||||
| Carcinoma of the ampulla of Vater | 1 | 21 | ||||
| Others | 3 | 25 | ||||
| Preoperative jaundice | Positive | 9 | 73 | 0.94 | ||
| Negative | 10 | 84 | ||||
| Preoperative biliary drainage | Positive | 12 | 92 | 0.70 | 0.90 (0.32–2.58) | 0.85 |
| Negative | 7 | 65 | ||||
| Preoperative cholangitis | Positive | 5 | 30 | 0.54 | ||
| Negative | 14 | 127 | ||||
| Operative time (min)a | 440 (94) | 449 (81) | 0.66 | |||
| Blood loss (ml)b | 666 (28–1280) | 588 (10–2450) | 0.89 | |||
| Blood transfusion | Positive | 2 | 31 | 0.53 | ||
| Negative | 17 | 126 | ||||
| Width of remnant bile duct (mm)a | 10.3 (3.2) | 10.8 (4.3) | 0.61 | |||
| Biliary stenting | Positive | 11 | 83 | 0.67 | ||
| Negative | 8 | 74 | ||||
| POPF Grade B or C | Positive | 8 | 76 | 0.63 | ||
| Negative | 11 | 81 | ||||
| DGE | Positive | 0 | 9 | 0.60 | ||
| Negative | 19 | 148 | ||||
| Bile leakage | Positive | 0 | 4 | 1.00 | ||
| Negative | 19 | 153 | ||||
| Postoperative pneumobilia | Positive | 17 | 115 | 0.14 | 1.67 (0.45–6.22) | 0.45 |
| Negative | 2 | 40 | ||||
PPDC post pancreaticoduodenectomy cholangitis, CI confidence interval, ASA-PS American Society of Anesthesiologists Physical Status
aData were presented as mean (standard deviation)
bData were presented as median (range)